{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-026626","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.562458+00:00","generated_at":"2026-06-12T07:27:03.062541+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"MyMD discusses Phase 2 results for MYMD-1 in sarcopenia/frailty; transcript furnished without specific data","bullets":["Conference call held August 2, 2023 to discuss Phase 2 results of oral TNF-α inhibitor MYMD-1.","Indication: chronic inflammation associated with sarcopenia (age-related frailty).","Transcript furnished as Exhibit 99.1 but appended text does not contain quantitative results.","Participants included Chairman Josh Silverman, President Chris Chapman, and CSO Adam Kaplin.","No safety or efficacy endpoints, trial sizes, or statistical outcomes disclosed in the provided exhibit excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-026626","json":"https://secwatch.observer/filing/0001493152-23-026626.json","markdown":"https://secwatch.observer/filing/0001493152-23-026626.md","text":"https://secwatch.observer/filing/0001493152-23-026626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223026626/0001493152-23-026626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223026626/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:27:03.062541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}